Akero Therapeutics announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year. The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis, will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability. Akero plans to hold an investor webcast detailing the findings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKRO:
- Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
- Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Akero Therapeutics reports Q2 EPS (60c), consensus (63c)
- Fly Insider: Exxon Mobil, Airbnb among week’s notable insider transactions
- 89bio price target raised to $37 from $30 at BTIG